Exploring the Role of Progression Free Survival in Chemotherapy Protocol: A Literatur Review: Telaah Pustaka Penilaian Progression Free Survival Sebagai Parameter Klinis Tata Terapi Kanker

Shyfa Anindya Padirja (Universitas Muhammadiyah Magelang)
Ngesti Rahayu (Universitas Muhammadiyah Magelang)
Tisa Fitria (Universitas Muhammadiyah Magelang)
Saniya Puspa Fasya (Universitas Muhammadiyah Magelang)
Nafa Umma (Universitas Muhammadiyah Magelang)
Salsabila Salma Zahrah (Universitas Muhammadiyah Magelang)
Setiyo Budi Santoso (Universitas Muhammadiyah Magelang)

Prosiding University Research Colloquium
Proceeding of The 18th University Research Colloquium 2023: Bidang MIPA dan Kesehatan

Progression-Free Survival (PFS) measures cancer patients' resistance to tumor progression. This alternative measurement is effective in assessing the performance of cancer therapy protocols and may serve an evidence for evaluating the quality of life of patients and planning follow-up treatments. Here in, we review a number of PFS data publications for drugs used in cancer therapy. The review involves ten scientific articles met the inclusion criteria provided by the PubMed database. Our finding present the optimal performance of chemotherapy protocols in preventing disease progression in seven various cancer populations. The highest PFS values for each cancer such as: crizotinib for lung cancer (28.71 months), enzalutamide for prostate cancer (7.1 months), pamiparib for stomach cancer (3.7 months), anlotinib for liver cancer (4.2 months), irinotecan plus raltitrexed for esophageal cancer (3.91 months), folfoxiri plus bevacizumab for metastatic colorectal cancer (10.7 months), and paclitaxel plus vistusertib for ovarian carcinoma (4.5 months).